
|Articles|March 3, 2010
NicOx partners with Bausch & Lomb for its candidate glaucoma drug
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
Advertisement
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
B&L will also be able to consider development and marketing of other products containing NCX 116 under the terms of the agreement. Phase II trials have been completed and clinical trials in patients with glaucoma and ocular hypertension are underway.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Tenpoint Therapeutics opens telehealth access to Yuvezzi for adults with presbyopia
2
City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease
3
The interplay between cardiac disease and the eye
4
Anti-VEGF switches for persistent fluid: A review of 3 clinical cases
5
















